MSN Labs launches Empagliflozin tablets for diabetes management

Hyderabad: Hyderabad-based MSN Laboratories (MSN Labs) launched Empagliflozin tablets (SGLT2i), a drug used for diabetes management, under the brand name ‘Empaone’. The medicine will cost Rs 15.90 and Rs 18.90 for each 10 mg and 25 mg tablet, respectively. India being the diabetic capital of the world with over 77 million people suffering from Type […]

Hyderabad: Hyderabad-based MSN Laboratories (MSN Labs) launched Empagliflozin tablets (SGLT2i), a drug used for diabetes management, under the brand name ‘Empaone’.

The medicine will cost Rs 15.90 and Rs 18.90 for each 10 mg and 25 mg tablet, respectively. India being the diabetic capital of the world with over 77 million people suffering from Type 2 diabetes, this medicine is expected to minimise the cost burden on patients and in turn improve compliance, the company stated.

---

Launch of Empaone assumes a critical role particularly for patients suffering from Type 2 diabetes and who were also affected with Covid-19, as diabetes has been found to be a major comorbidity factor in such cases.

The company said diabetes, if not effectively managed, can lead to multiple and severe health complications. MSN has developed the active pharmaceutical ingredient (API) and the finished dosage formulation (FDF) of Empaone, its in-house R&D centre at IDA, Pashamylaram, Patancheru.

The drug development is fully indigenous right from conceptualisation to API development and FDF at the company.

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .